-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hengrui Medicine's Class 1 new drug Proline Henggliflozin Tablets (trade name: Ruiqin) was officially approved for marketing, which is also the first domestically-made innovative SGLT2 inhibitor approved so far
.
Proline constantagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which reduces blood sugar by inhibiting the reabsorption of glucose by the kidneys, lowering the renal glucose threshold, and promoting urinary glucose excretion
.
Proline Hengagliflozin Tablets is approved for improving glycemic control in adults with type 2 diabetes mellitus
According to the latest report of the International Diabetes Federation (IDF) in 2021, there are about 537 million people with diabetes in the world, and it is expected to jump to a staggering 783 million by 2045
.
The incidence of type 2 diabetes in Chinese adults has reached 10.
According to the forecast of EvaluatePharma, a well-known industry research organization, in 2022, the share of SGLT2 inhibitors will surpass that of DPP4 inhibitors and become the world's No.
1 oral hypoglycemic drug
.
The domestic market structure of hypoglycemic drugs is still dominated by traditional hypoglycemic drugs.
At present, Proline Henggliflozin Tablets are still in the development of compound preparations with metformin and DPP4 inhibitors
.
In the field of biological preparations, Hengrui has deployed long-acting insulin INS068, long-acting insulin/GLP-1 compound preparation HR17031, and GLP-1 analog noriglycopeptide; at the end of last year, it also launched a clinical trial of super-fast-acting insulin HR011408; In terms of -1/GIP dual-target agonists, Hengrui has also made a layout
This time, another innovative drug of Hengrui Medicine was approved at the same time as Henggliflozin, the first CDK4/6 inhibitor Dalsili in China.
